GRI Bio (GRI) vs HCW Biologics (HCWB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GRI Bio is the larger company by market cap ($3.8 million vs $3.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRI | HCWB |
|---|---|---|
| Share price | $1.74 | $1.60 |
| Market cap | $3.80M | $3.58M |
| 1-day change | +3.57% | +4.58% |
| EPS (TTM) | $-14.71 | $-19.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $64.12 | $27.57 |
| 52-week low | $1.36 | $1.50 |
| Distance from 52-week high | -97.29% | -94.20% |
| Analyst consensus | none | buy |
| Avg. price target upside | +963.22% | +2900.00% |
| Average volume | 328.24K | 376.23K |
| Shares outstanding | 2.19M | 2.24M |
| Employees | 3 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GRI Bio
GRI stock →GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
GRI vs HCWB FAQ
Which is bigger, GRI Bio or HCW Biologics?
GRI Bio (GRI) is larger, with a market capitalization of $3.80M compared with $3.58M for HCW Biologics (HCWB).
Are GRI Bio and HCW Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.